Phreesia, Inc. (NYSE:PHR) Director Michael Weintraub Sells 861 Shares

Phreesia, Inc. (NYSE:PHR) Director Michael Weintraub sold 861 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $25.26, for a total transaction of $21,748.86. Following the transaction, the director now owns 242,827 shares in the company, valued at $6,133,810.02. This represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Weintraub also recently made the following trade(s):

• On Friday, December 13th, Michael Weintraub sold 20,565 shares of Phreesia stock. The stock was sold at an average price of $25.04, for a total transaction of $514,947.60.
• On Monday, December 2nd, Michael Weintraub sold 15,152 shares of Phreesia stock. The stock was sold at an average price of $21.01, for a total value of $318,343.52.

Phreesia Trading Down 3.0 %

NYSE:PHR opened at $24.87 on Wednesday. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -16.92 and a beta of 0.98. The company’s 50 day moving average price is $20.60 and its 200-day moving average price is $21.88. The company has a quick ratio of 1.77, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.58) EPS. On average, equities research analysts forecast that Phreesia, Inc. will post -1.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Phreesia

Several hedge funds and other institutional investors have recently bought and sold shares of PHR. International Assets Investment Management LLC raised its holdings in shares of Phreesia by 2,179.7% during the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after purchasing an additional 1,395 shares during the last quarter. nVerses Capital LLC raised its stake in Phreesia by 76.5% during the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after buying an additional 1,300 shares during the last quarter. Lombard Odier Asset Management USA Corp purchased a new stake in Phreesia during the 2nd quarter valued at $202,000. Point72 DIFC Ltd bought a new position in shares of Phreesia during the 2nd quarter valued at $209,000. Finally, XTX Topco Ltd purchased a new position in shares of Phreesia in the 3rd quarter worth $247,000. Institutional investors own 92.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PHR. JMP Securities restated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $29.00 target price on shares of Phreesia in a report on Tuesday, December 10th. Canaccord Genuity Group reiterated a “buy” rating and issued a $34.00 price target on shares of Phreesia in a research note on Thursday, September 5th. JPMorgan Chase & Co. boosted their price objective on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Monday, September 9th. Finally, Truist Financial raised their target price on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.